Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of atropine sulfate in preparing medicine for treating primary liver cancer

A technology for atropine sulfate and primary liver cancer, which can be used in drug combinations, anti-tumor drugs, active ingredients of heterocyclic compounds, etc., can solve the problems of cardiotoxicity risk hindering clinical application research, and achieve the effect of rapid recovery of liver function

Active Publication Date: 2017-11-24
ANHUI PROVINCIAL CANCER HOSPITAL
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] Although verapamil can inhibit tumor chemotherapy resistance and prolong patient survival in early clinical cohort studies of breast and ovarian cancer, its risk of cardiotoxicity hinders further in-depth clinical application research

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of atropine sulfate in preparing medicine for treating primary liver cancer
  • Application of atropine sulfate in preparing medicine for treating primary liver cancer

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0009] Below in conjunction with specific embodiment, further illustrate the present invention. It should be understood that these examples are for illustration only

[0010] invention and not intended to limit the scope of the invention.

[0011] 1. Case selection

[0012] 1.1 Inclusion criteria

[0013] All patients met the clinical diagnostic criteria for primary liver cancer (standards established by the Liver Cancer Professional Committee of the Chinese Anti-Cancer Association in 2001); KPS score ≥ 70 points; patients aged 18 to 70 years old; cardiac function grade 0 to I; liver function CHILD classification Grade B or above; the expected survival time is more than 3 months, and the Seldinger catheter can enter the patient in the artery feeding the malignant tumor. All patients voluntarily accepted the application of this regimen and signed the informed consent, and the study was approved by the hospital ethics committee;

[0014] 1.2 Exclusion criteria

[0015] Pati...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides application of atropine sulfate in preparing a medicine for treating the primary liver cancer. Verapamil subjected to vein application cannot reach the medicine-resistant concentration for effectively reversing tumor cells and has cardiotoxicity. The application provided by the invention has the beneficial effects that atropine can relieve the arrhythmia possibly caused by use of the verapamil by eliminating suppression of the vagus nerve to the heart and accelerating the heart beat, so that the treating effect of the verapamil combined with chemotherapeutic medicines in treating the primary liver cancer is improved.

Description

technical field [0001] The invention relates to the use of atropine sulfate in the preparation of medicines for treating primary liver cancer. Background technique [0002] Verapamil (Verapamil) is a calcium ion channel blocker widely used in clinical practice for heart disease. It has the effect of reversing tumor cell MDR (multidrug resistance). The concentration of verapamil to effectively reverse tumor MDR in vitro is 6-10 μmol / L (2.94-4.91 μg / mL), and when its concentration in peripheral venous blood reaches 1-2 μmol / L (0.49-0.98 μg / mL), severe arrhythmia and atrioventricular block will occur Etc. Therefore, intravenous application cannot reach the effective concentration for reversing drug resistance. [0003] Although early clinical cohort studies of breast and ovarian cancer confirmed that verapamil can inhibit tumor chemotherapy resistance and prolong the survival time of patients, its risk of cardiotoxicity hinders further in-depth clinical application research. ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/46A61P35/00
CPCA61K31/46
Inventor 范平生张腾跃钱立庭刘亚贝黄金
Owner ANHUI PROVINCIAL CANCER HOSPITAL
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com